SlideShare a Scribd company logo
.                  .

.   ,       , J.S.S.   ,
•                    :




                                                                      /




                                                          :
•                    :

                           .

Disease, its cause, what may abate the ill:
Let leech examine these, then use his skill.                  :



               .           ,                   , J.S.S.           ,
:                      (pig, cow)



        :                        ,                     ,                ,



             :                                ,
                                          ,

                                ,


            If (food and work are either) excessive or deficient, the three things
            enumerated by (medical) writers, flatulence, biliousness, and phlegm,
            will cause (one) disease.

.   ,                    , J.S.S.                      ,
/




                      ,

               /            /                ,




        If (one's food has been) digested let one eat with moderation;
        (for) that is the way to prolong the life of an embodied soul.

.   ,               , J.S.S.                     ,
.   ,   , J.S.S.   ,
-
                                                           –             /
        ,


                                                                                                          ,

                                            (SAR)              .
                                                           ,
                       ,
                .

,                                              .[

                                                .
            ,                                                                             ,
                                                                                      .          6
                                                                     ,
                               .


                5000
    ,                                               ,                                                         .
                                                                              :
                                       (First) assure yourself that your food has been digested and never fail
                                       to eat, when very hungry, whatever is not disagreeable (to you).

                .                  ,                , J.S.S.                      ,
Clinical testing

• {Phase 0 (non-clinical)}
• Phase 1 (volunteers)
• Phase 2 (patients)
• Phase 3 (large scale multi-centre Patients)
• Phase 4 (post registration monitoring)
)




        There will be no disaster to one's life if one eats with moderation,
        food that is not disagreeable.

.   ,                 , J.S.S.                       ,
As pleasure dwells with him who eats moderately, so disease (dwells)
        with the glutton who eats voraciously.

.   ,                , J.S.S.                      ,
Clinical Trials- Phase I
    Drug is tested on healthy volunteers to determine toxicity
   relative to dose and to screen for unexpected side effects..
Small group of people (20-80)

HEALTHY VOLUNTEERS

INFORMED CONSENT
       EVALUATE ITS SAFETY

    COMMON SIDE EFFECTS
Fatigue, nausea, hair loss,
vomiting
     IDENTIFY SIDE EFFFECTS

Determine safe dosage range

0.5-1.5 YEARS

ETHICAL APPROVAL
SINGLE & REPEAT DOSE

Full Rescussitation + Medical Backup + Monitor
Clinical Trials- Phase II
Drug is tested on small group of patients to see if drug has any
 beneficial effect and to determine the dose level needed for
                           this effect.


                                                       PATIENTS
 Larger Group of People (100-300)

     INFORMED CONSENT                               EFFECTIVENESS

                                               MAXIMUM MONITORING
      EVALUATE ITS SAFETY
                                                 FULL RESCUSSITATION
            DOSAGE

        TYPE OF PATIENT                          INDICATION FOR USE

      SEVERITY OF DISEASE                            DOSE RANGE

    PK STUDIES IN ILL PEOPLE                   SCHEDULE & INCREMENT

     NATURE OF SIDE EFFECTS & SEVERITY; EFFECTS IN SPECIAL GRUOPS
Clinical Trials- Phase III

Drug is tested on much larger group of patients and compared
          with existing treatments and with a placebo
1500-3500 Patients
Multicentre
More certain data for the objectives
of phase 2 studies
Interactions between drugs
start to become measurable
in the larger population
sub-groups start to be
established
special features and
problems show up
Monitor side effects

Confirm its effectiveness

Drug Vs Placebo
He will be afflicted with numberless diseases, who eats immoderately,
        ignorant (of the rules of health).

.   ,                , J.S.S.                      ,
Launch Drug after P-III
Clinical Trials Phase IV
• Phase IV: Drug is placed on the market and patients
  are monitored for side effects
The learned (physician) should ascertain the condition of his patient;
        the nature of his disease, and the season (of the year) and (then)
        proceed (with his treatment).
.   ,                 , J.S.S.                      ,
.   ,   , J.S.S.   ,
-
                                                – D.PHARM
                                         -
                                                   – B.PHARM

                                                   – M.PHARM            13                  /
                                                                               -Pharmaceutics
                                                                                – Pharm. Chemistry
                                                            /           – Pharmacology/Toxicology
                                                                              - Pharmacognosy
                                                                                      Pharm Biotechnology
                                                                                 – Pharm. Analysis
                                                            -                – Pharm Quality Assurance
Medical science consists of four parts, viz.,                            – Pharmacy Practice
patient, physician, medicine and compounder;
and each of these (again) contains four sub-                                    –Phram. Regulatory Affairs
divisions.
                                                                                     – Industrial Pharmacy
                                                                Phytopharmacy& Phytomedicine
                                                                    &           Clinical Practice & Research
                                                                                – Pharama Marketing

                PHARM. D.,                                                                      - Ph.D.,
– Pharm. Chemistry                      – Pharm. Chemistry
    – Pharm. Chemistry
                                                                  /




                                                                                              /
                                                              -

                                                                                          -




                   /
                                                    /
                                                                                      -
               -
                                                    -                                     B.PHARM
&                        D.PHARM
                                                    D.PHARM
                            -
                       B.PHARM
                                                          -
                                                        B.PHARM

                                               &




                                           D.PHARM

                                                -

                                          B.PHARM                         D.PHARM                 &

                                                                             -
.                  ,               , J.S.S.                           ,
– D.PHARM   (2 Years)
          -
          HSC – PCMB, PCZB,

            – B.PHARM   (4 Years)

     HSC – PCMB, PCZB, 40%

PHARM. D., (6 Years)

     HSC – PCMB, PCZB, 35%
•   INDUSTRY
•   ACADEMIC
•   MARKETING
•   GOVERNMENT JOBS
•   IT INDUSTRY
•   CLINICAL
•   HIGHER STUDIES
•   PHARMACIST
•   INTERNATIONAL
    OPPORTUNITIES
JSS UNIVERSITY, MYSORE
UDHAGAMANDALAM              • MYSURU
B.PHARM                     B.PHARM
M.PHARM (12 BRANCHES)       M.PHARM (12 BRANCHES)
PHARM D                     PHARM D
PhD                         PhD
PG DIPLOMA COURSES          PG DIPLOMA COURSES
CERTIFICATE COURSE          CERTIFICATE COURSE
WELL EQUPPED LABS           WELL EQUPPED LABS
5TH RANK (ALL OVER INDIA)   13TH RANK (ALL OVER
PLACEMENTS                  INDIA)
                            PLACEMENTS
No medicine is necessary for him who eats after assuring (himself) that what
he has (already) eaten has been digested.




               .          ,                     , J.S.S.                  ,

More Related Content

Viewers also liked

E mas F 36
E mas F 36E mas F 36
E mas F 36
norwich1981
 
L'associació com a eina per als diabètics. ADC a Lleida
L'associació com a eina per als diabètics. ADC a LleidaL'associació com a eina per als diabètics. ADC a Lleida
L'associació com a eina per als diabètics. ADC a Lleida
Pediatriadeponent
 
The Airport of the Future
The Airport of the FutureThe Airport of the Future
The Airport of the Future
Dimitris Bountolos
 
T7 - Nuevas necesidades, nuevos materiales
T7 - Nuevas necesidades, nuevos materialesT7 - Nuevas necesidades, nuevos materiales
T7 - Nuevas necesidades, nuevos materialesÁngel González Olinero
 
Storage and Dispensing Platforms - DENIOS US
Storage and Dispensing Platforms - DENIOS USStorage and Dispensing Platforms - DENIOS US
Storage and Dispensing Platforms - DENIOS US
DENIOS US, Chemical Storage Buildings and Workplace Safety Products
 
eGestion del tiempo1
eGestion del tiempo1eGestion del tiempo1
eGestion del tiempo1
memin987
 
Tylösandsseminariet 2015 – 15.15 2 Olof Stenlund unga vuxnas beteenden
Tylösandsseminariet 2015 – 15.15 2 Olof Stenlund unga vuxnas beteendenTylösandsseminariet 2015 – 15.15 2 Olof Stenlund unga vuxnas beteenden
Tylösandsseminariet 2015 – 15.15 2 Olof Stenlund unga vuxnas beteenden
MHF Tylösandsseminariet
 
Cd6451b Es Dfu Deu
Cd6451b Es Dfu DeuCd6451b Es Dfu Deu
Cd6451b Es Dfu Deuguestfeb8444
 
Mvd spanish dl_manual
Mvd spanish dl_manualMvd spanish dl_manual
Mvd spanish dl_manual
Universidad Central del ecuador
 
City and Harris County Resource Guide for VET
City and Harris County Resource Guide for VETCity and Harris County Resource Guide for VET
City and Harris County Resource Guide for VETTam Nguyen
 
A 5 atencion_fav_presencial
A 5 atencion_fav_presencialA 5 atencion_fav_presencial
A 5 atencion_fav_presencialPgs Salinas
 
Crear un video poema con Windows Movie Maker o Photopeach
Crear un video poema con Windows Movie Maker o PhotopeachCrear un video poema con Windows Movie Maker o Photopeach
Crear un video poema con Windows Movie Maker o Photopeach
Fernández Gorka
 
8 Trends That Will Define the Future of Email Marketing
8 Trends That Will Define the Future of Email Marketing8 Trends That Will Define the Future of Email Marketing
8 Trends That Will Define the Future of Email Marketing
Chad S. White
 
¿Cómo hacer una campaña digital efectiva (efectiva con presupuesto limitado),...
¿Cómo hacer una campaña digital efectiva (efectiva con presupuesto limitado),...¿Cómo hacer una campaña digital efectiva (efectiva con presupuesto limitado),...
¿Cómo hacer una campaña digital efectiva (efectiva con presupuesto limitado),...
Susy Obregón Rodas
 

Viewers also liked (15)

E mas F 36
E mas F 36E mas F 36
E mas F 36
 
L'associació com a eina per als diabètics. ADC a Lleida
L'associació com a eina per als diabètics. ADC a LleidaL'associació com a eina per als diabètics. ADC a Lleida
L'associació com a eina per als diabètics. ADC a Lleida
 
The Airport of the Future
The Airport of the FutureThe Airport of the Future
The Airport of the Future
 
T7 - Nuevas necesidades, nuevos materiales
T7 - Nuevas necesidades, nuevos materialesT7 - Nuevas necesidades, nuevos materiales
T7 - Nuevas necesidades, nuevos materiales
 
Storage and Dispensing Platforms - DENIOS US
Storage and Dispensing Platforms - DENIOS USStorage and Dispensing Platforms - DENIOS US
Storage and Dispensing Platforms - DENIOS US
 
eGestion del tiempo1
eGestion del tiempo1eGestion del tiempo1
eGestion del tiempo1
 
Tylösandsseminariet 2015 – 15.15 2 Olof Stenlund unga vuxnas beteenden
Tylösandsseminariet 2015 – 15.15 2 Olof Stenlund unga vuxnas beteendenTylösandsseminariet 2015 – 15.15 2 Olof Stenlund unga vuxnas beteenden
Tylösandsseminariet 2015 – 15.15 2 Olof Stenlund unga vuxnas beteenden
 
Cd6451b Es Dfu Deu
Cd6451b Es Dfu DeuCd6451b Es Dfu Deu
Cd6451b Es Dfu Deu
 
Mvd spanish dl_manual
Mvd spanish dl_manualMvd spanish dl_manual
Mvd spanish dl_manual
 
City and Harris County Resource Guide for VET
City and Harris County Resource Guide for VETCity and Harris County Resource Guide for VET
City and Harris County Resource Guide for VET
 
A 5 atencion_fav_presencial
A 5 atencion_fav_presencialA 5 atencion_fav_presencial
A 5 atencion_fav_presencial
 
proj
projproj
proj
 
Crear un video poema con Windows Movie Maker o Photopeach
Crear un video poema con Windows Movie Maker o PhotopeachCrear un video poema con Windows Movie Maker o Photopeach
Crear un video poema con Windows Movie Maker o Photopeach
 
8 Trends That Will Define the Future of Email Marketing
8 Trends That Will Define the Future of Email Marketing8 Trends That Will Define the Future of Email Marketing
8 Trends That Will Define the Future of Email Marketing
 
¿Cómo hacer una campaña digital efectiva (efectiva con presupuesto limitado),...
¿Cómo hacer una campaña digital efectiva (efectiva con presupuesto limitado),...¿Cómo hacer una campaña digital efectiva (efectiva con presupuesto limitado),...
¿Cómo hacer una campaña digital efectiva (efectiva con presupuesto limitado),...
 

Recently uploaded

June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Jheel Barad
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 

Recently uploaded (20)

June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 

Career in pharmacy in tamil jsknagarajan

  • 1. . . . , , J.S.S. ,
  • 2. : / : • : . Disease, its cause, what may abate the ill: Let leech examine these, then use his skill. : . , , J.S.S. ,
  • 3. : (pig, cow) : , , , : , , , If (food and work are either) excessive or deficient, the three things enumerated by (medical) writers, flatulence, biliousness, and phlegm, will cause (one) disease. . , , J.S.S. ,
  • 4. / , / / , If (one's food has been) digested let one eat with moderation; (for) that is the way to prolong the life of an embodied soul. . , , J.S.S. ,
  • 5. . , , J.S.S. ,
  • 6. - – / , , (SAR) . , , . , .[ . , , . 6 , . 5000 , , . : (First) assure yourself that your food has been digested and never fail to eat, when very hungry, whatever is not disagreeable (to you). . , , J.S.S. ,
  • 7. Clinical testing • {Phase 0 (non-clinical)} • Phase 1 (volunteers) • Phase 2 (patients) • Phase 3 (large scale multi-centre Patients) • Phase 4 (post registration monitoring)
  • 8. ) There will be no disaster to one's life if one eats with moderation, food that is not disagreeable. . , , J.S.S. ,
  • 9. As pleasure dwells with him who eats moderately, so disease (dwells) with the glutton who eats voraciously. . , , J.S.S. ,
  • 10. Clinical Trials- Phase I Drug is tested on healthy volunteers to determine toxicity relative to dose and to screen for unexpected side effects.. Small group of people (20-80) HEALTHY VOLUNTEERS INFORMED CONSENT EVALUATE ITS SAFETY COMMON SIDE EFFECTS Fatigue, nausea, hair loss, vomiting IDENTIFY SIDE EFFFECTS Determine safe dosage range 0.5-1.5 YEARS ETHICAL APPROVAL SINGLE & REPEAT DOSE Full Rescussitation + Medical Backup + Monitor
  • 11. Clinical Trials- Phase II Drug is tested on small group of patients to see if drug has any beneficial effect and to determine the dose level needed for this effect. PATIENTS Larger Group of People (100-300) INFORMED CONSENT EFFECTIVENESS MAXIMUM MONITORING EVALUATE ITS SAFETY FULL RESCUSSITATION DOSAGE TYPE OF PATIENT INDICATION FOR USE SEVERITY OF DISEASE DOSE RANGE PK STUDIES IN ILL PEOPLE SCHEDULE & INCREMENT NATURE OF SIDE EFFECTS & SEVERITY; EFFECTS IN SPECIAL GRUOPS
  • 12. Clinical Trials- Phase III Drug is tested on much larger group of patients and compared with existing treatments and with a placebo 1500-3500 Patients Multicentre More certain data for the objectives of phase 2 studies Interactions between drugs start to become measurable in the larger population sub-groups start to be established special features and problems show up Monitor side effects Confirm its effectiveness Drug Vs Placebo
  • 13. He will be afflicted with numberless diseases, who eats immoderately, ignorant (of the rules of health). . , , J.S.S. ,
  • 15. Clinical Trials Phase IV • Phase IV: Drug is placed on the market and patients are monitored for side effects
  • 16. The learned (physician) should ascertain the condition of his patient; the nature of his disease, and the season (of the year) and (then) proceed (with his treatment). . , , J.S.S. ,
  • 17. . , , J.S.S. ,
  • 18. - – D.PHARM - – B.PHARM – M.PHARM 13 / -Pharmaceutics – Pharm. Chemistry / – Pharmacology/Toxicology - Pharmacognosy Pharm Biotechnology – Pharm. Analysis - – Pharm Quality Assurance Medical science consists of four parts, viz., – Pharmacy Practice patient, physician, medicine and compounder; and each of these (again) contains four sub- –Phram. Regulatory Affairs divisions. – Industrial Pharmacy Phytopharmacy& Phytomedicine & Clinical Practice & Research – Pharama Marketing PHARM. D., - Ph.D.,
  • 19. – Pharm. Chemistry – Pharm. Chemistry – Pharm. Chemistry / / - - / / - - - B.PHARM & D.PHARM D.PHARM - B.PHARM - B.PHARM & D.PHARM - B.PHARM D.PHARM & - . , , J.S.S. ,
  • 20. – D.PHARM (2 Years) - HSC – PCMB, PCZB, – B.PHARM (4 Years) HSC – PCMB, PCZB, 40% PHARM. D., (6 Years) HSC – PCMB, PCZB, 35%
  • 21. INDUSTRY • ACADEMIC • MARKETING • GOVERNMENT JOBS • IT INDUSTRY • CLINICAL • HIGHER STUDIES • PHARMACIST • INTERNATIONAL OPPORTUNITIES
  • 22. JSS UNIVERSITY, MYSORE UDHAGAMANDALAM • MYSURU B.PHARM B.PHARM M.PHARM (12 BRANCHES) M.PHARM (12 BRANCHES) PHARM D PHARM D PhD PhD PG DIPLOMA COURSES PG DIPLOMA COURSES CERTIFICATE COURSE CERTIFICATE COURSE WELL EQUPPED LABS WELL EQUPPED LABS 5TH RANK (ALL OVER INDIA) 13TH RANK (ALL OVER PLACEMENTS INDIA) PLACEMENTS
  • 23. No medicine is necessary for him who eats after assuring (himself) that what he has (already) eaten has been digested. . , , J.S.S. ,